Loading
In the first randomised trial dedicated to non-clear cell kidney cancers, sunitinib delayed progression more than everolimus overall, though chromophobe tumours appeared to fare better on everolimus.
Randomised phase 2 trial of 108 patients with metastatic papillary, chromophobe or unclassified renal cell carcinoma randomised to sunitinib or everolimus.
Median progression-free survival was 8.3 months with sunitinib against 5.6 months with everolimus (hazard ratio 1.41 for everolimus); in the small chromophobe subgroup everolimus gave longer progression-free survival (11.4 versus 5.5 months), while papillary tumours did better with sunitinib.
VEGF-directed therapy is the default for non-clear cell disease, with everolimus considered in chromophobe tumours; cabozantinib later became preferred for papillary disease.
Shares Chromophobe renal cell carcinoma, Papillary renal cell carcinoma.
Shares Sunitinib, Everolimus.
Shares Papillary renal cell carcinoma, Sunitinib.
Shares Papillary renal cell carcinoma, Sunitinib.
Shares Papillary renal cell carcinoma, Sunitinib.
Shares Sunitinib, Everolimus.
Shares Sunitinib, Everolimus.